Featured Research

from universities, journals, and other organizations

Targeted delivery of losartan reduces liver inflammation and scarring, study finds

Date:
March 1, 2010
Source:
Wiley-Blackwell
Summary:
A recent study found that rats with advanced fibrosis that were administered a short-term dose of losartan-M6PHSA had reduced liver inflammation and fibrosis. Those animals treated with oral losartan alone did not experience a similar reduction in disease activity.

A recent study found that rats with advanced fibrosis that were administered a short-term dose of losartan-M6PHSA had reduced liver inflammation and fibrosis. Those animals treated with oral losartan alone did not experience a similar reduction in disease activity.

Results of this study appear in the March issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

Liver fibrosis a consequence of liver disease was thought to be irreversible and only transplantation of the liver would offer survival to the patient. Doctors now believe that early detection of fibrosis offers potential for therapies that prevent further liver scarring and the imminent need for transplantation.

In the current study, a Spanish research team led Ramón Bataller, M.D., from the Hospital Clínic in Barcelona investigated such a treatment, losartan-M6PHSA, in rat models. Losartan is an angiotensin (AT1) receptor blocker that was linked to mannose-6-phosphate modified human serum albumin (M6PHSA), a selective drug carrier targeting hepatic stellate cells (HSC). An average of 7 losartan molecules were coupled to M6PHSA. The study verified that losartan-M6PHSA accumulates in the fibrotic liver only, and other organs such as the lungs, heart, spleen and kidneys did not display the conjugate.

Researchers induced liver fibrosis in male rats by bile duct ligation to study short-term treatment outcomes. In both models, rats were given daily injections of saline, losartan-M6PHSA (3.3 mg/kg/day, to 125 µg losartan/kg), M6PHSA alone (3.3 mg/kg/day), or oral losartan (5 mg/kg/day). Bile duct-ligated rates treated with saline of M6PHSA alone showed severe fibrosis. "Animals treated with losartan-M6PHSA displayed less collagen deposition with less frequent formation of bridging fibrosis," said Dr. Bataller. "Short-term oral treatment with losartan alone did not reduce fibrosis or the amount of collagen."

In the long-term results, advanced liver fibrosis was established in male rats by chronic treatment of carbon tetrachloride (CCl4 ). Treatment by saline, losartan-M6PHSA or M6PHSA alone was administered twice a week for three weeks. "While losartan-M6PHSA was able to reduce collagen synthesis, the degree of fibrosis reduction was not significant. Further studies identifying the ideal route and drug dosage for long-term treatment are clearly required," concluded Dr. Bataller.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Montserrat Moreno, Teresa Gonzalo, Robbert J. Kok, Pau Sancho-Bru, Marike van Beuge, Josine Swart, Jai Prakash, Kai Temming, Constantino Fondevila, Leonie Beljaars, Marie Lacombe, Paul Vd Hoeven, Vicente Arroyo, Klaas Poelstra, David A. Brenner, Pere Ginès and Ramón Bataller. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology, 2010; NA DOI: 10.1002/hep.23419

Cite This Page:

Wiley-Blackwell. "Targeted delivery of losartan reduces liver inflammation and scarring, study finds." ScienceDaily. ScienceDaily, 1 March 2010. <www.sciencedaily.com/releases/2010/03/100301091314.htm>.
Wiley-Blackwell. (2010, March 1). Targeted delivery of losartan reduces liver inflammation and scarring, study finds. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2010/03/100301091314.htm
Wiley-Blackwell. "Targeted delivery of losartan reduces liver inflammation and scarring, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/03/100301091314.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) — The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) — A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) — The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
'Cadaver Dog' Sniffs out Human Remains

'Cadaver Dog' Sniffs out Human Remains

AP (Oct. 21, 2014) — Where's a body buried? Buster's nose can often tell you. He's a cadaver dog, specially trained to find human remains and increasingly being used by law enforcement and accepted in courts. These dogs are helping solve even decades-old mysteries. (Oct. 21) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins